Treatment of patients with acute coronary syndrome and atrial fibrillation

Authors

DOI:

https://doi.org/10.15587/2519-4798.2019.170467

Keywords:

anticoagulant therapy, antiplatelet therapy, dual therapy, triple therapy, atrial fibrillation, acute coronary syndrome

Abstract

The aim was to study the possible protective effect of drug therapy regarding the development of AF in patients with ACS and compliance with the standards of treatment of these patients in everyday clinical practice.

Materials and research methods. A study was conducted of 125 patients with ACS who were hospitalized with ACS to the center of percutaneous coronary interventions of the KNP of the Kharkiv Regional Council "Regional Clinical Hospital" for four years from 2015-2018, among which 65 had atrial fibrillation . The criterion for inclusion in the study was the presence of ACS; exclusion criteria were the presence of severe concomitant diseases (active oncological processes, chronic IV degree renal failure, etc.), heart defects, and the patient’s refusal to participate in the study. In accordance with the Helsinki Declaration, all patients were informed about the aim, methods and design of the study and gave their consent to participate.

Patients were divided into groups according to the presence of AF. In group 1, patients with AF were combined, and patients who had AF for the first time during hospitalization for ACS were subgroup 1a (n=41); patients in whom AF was observed before the development of ACS were subgroup 1b (n=24). The second group consisted of patients without indications of AF in the history and during hospitalization (n=60).

Results. The majority of patients of the 1st group, namely, 92.3 %, had three or more points on the CHA2DS2-VASc scale of thromboembolic complications, while the greatest number of patients (n=41, 63 %) with ACS and AF were 4-5 points on the scale of risk of thromboembolic complications according to CHA2DS2-VASc. Most patients had a score of 0-1 on the bleeding risk scale. When evaluating drug therapy in patients with ACS, it was found that acetylsalicylic acid was administered to almost all patients with ACS, except for patients with concomitant bronchial asthma. The majority of patients with ACS, with or without concomitant AF, received clopidogrel as a double antiplatelet therapy along with acetylsalicylic acid. Anticoagulant therapy with the use of warfarin and new oral anticoagulants was more often prescribed to patients with 1b subgroups. Calcium antagonists were more frequently prescribed in patients of the 2nd group compared with the 1st (n1=4; 6.2 % vs n2=12; 20.0 %, p=0.0228). Statins were administered to hospitals in almost all patients, except for a few patients with intact coronary vessels. Prehospital administration of the loading dose of the P2Y12 inhibitor was more frequently recorded in the 1st group of patients as compared with the 2nd (n1=26; 40.0 % vs n2=13; 21.7 %, p=0.0292), at the same time among patients with 1a-subgroups with AF, which appeared for the first time, a significantly rarer prescription of the pre-hospital loading dose of the P2Y12 inhibitor was observed compared with the 1b-subgroup (n1a=11; 26.8 % vs n1b=15; 62.5 %, p=0 , 0061). The majority of patients in all groups received ACE inhibitors / ARBs in basic therapy during the hospital period. The prescription of diuretics was more often registered among patients of the 1b-subgroup, which indicates a more severe course of CHF in this group of patients, which preceded the development of ACS. An increase in the frequency of triple therapy prescriptions among patients with AF over the years 2015-2018 was found, which corresponds to the existing modern standards of medical care regarding the appointment of combination anticoagulant and anti-platelet therapy to patients with AF and ACS. Unassigned triple therapy in the group of patients with AF, which originated for the first time, is associated with a greater frequency of registration of anemia in this group of patients.

Conclusion. In accordance with the results of the study, all patients with ACS and AF have a high thromboembolic risk and require anti-coagulant therapy. In everyday clinical practice, in the discharge of patients with ACS and AF from hospital more than a third (38.1 %) patients are not recommended anticoagulant therapy, which does not comply with current recommendations. At the same time, patients are more often prescribed therapy who had AF before the development of ACS, while patients in subgroup 1a who have AF demonstrated in the acute period have less than half. In a retrospective analysis of extracts of case histories over the period 2015-2018, an increase in the frequency of triple therapy prescriptions among patients with AF was found. The most common cause of non-prescribing anticoagulants is anemia and a high risk of bleeding.

Author Biography

Ben Salem Fedia, Kharkiv Medical Academy of Postgraduate Education Amosova str., 4, Kharkiv, Ukraine, 61176

Department of Cardiology and Functional Diagnostics

References

  1. Tseluiko, V. I.; Tseluiko, V. I. (Ed.) (2014). Spravochnik po kardiologii. Kyiv: Zdorove Ukrainy, 542.
  2. Batra, G., Svennblad, B., Held, C., Jernberg, T., Johanson, P., Wallentin, L., Oldgren, J. (2016). All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome. Heart, 102 (12), 926–933. doi: http://doi.org/10.1136/heartjnl-2015-308678
  3. Van den Berg, N. W. E., de Groot, J. R. (2015). Myocardial infarction, atrial fibrillation and mortality: timing is everything. Netherlands Heart Journal, 23 (9), 428–429. doi: http://doi.org/10.1007/s12471-015-0710-9
  4. Chao, T.-F., Huang, Y.-C., Liu, C.-J., Chen, S.-J., Wang, K.-L., Lin, Y.-J. et. al. (2014). Acute myocardial infarction in patients with atrial fibrillation with a CHA2DS2-VASc score of 0 or 1: A nationwide cohort study. Heart Rhythm, 11 (11), 1941–1947. doi: http://doi.org/10.1016/j.hrthm.2014.08.003
  5. Kea, B., Manning, V., Alligood, T., Raitt, M. (2016). A Review of the Relationship of Atrial Fibrillation and Acute Coronary Syndrome. Current Emergency and Hospital Medicine Reports, 4 (3), 107–118. doi: http://doi.org/10.1007/s40138-016-0105-2
  6. Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Hacke, W., Oldgren, J. et. al. (2013). EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary†. European Heart Journal, 34 (27), 2094–2106. doi: http://doi.org/10.1093/eurheartj/eht134
  7. Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.-C., Hacke, W. et. al. (2015). Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace, 17 (10), 1467–1507. doi: http://doi.org/10.1093/europace/euv309
  8. January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C. et. al. (2014). AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology, 64 (21), 2246–2280. doi: http://doi.org/10.1016/j.jacc.2014.03.021
  9. Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B. et. al. (2016). ESC Scientific Document Group; 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 37 (38), 2893–2962. doi: http://doi.org/10.1093/eurheartj/ehw210
  10. Cannon, C. P., Bhatt, D. L., Oldgren, J., Lip, G. Y. H., Ellis, S. G., Kimura, T. et. al. (2017). Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. New England Journal of Medicine, 377 (16), 1513–1524. doi: http://doi.org/10.1056/nejmoa1708454
  11. Bencivenga, L., Komici, K., Corbi, G., Cittadini, A., Ferrara, N., Rengo, G. (2018). The Management of Combined Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Particularly Complex Challenge, Especially in the Elderly. Frontiers in Physiology, 9. doi: http://doi.org/10.3389/fphys.2018.00876
  12. Lang, T. A., Sesik, M.; Leonov, V. P. (Ed.) (2011). Kak opisyvat statistiku v meditsine. Moscow: Prakticheskaia meditsina, 480.
  13. Lapach, S. N., Chubenko, A. V., Babich, P. N. (2001). Statisticheskie metody v mediko-biologicheskikh issledovaniiakh s ispolzovaniem Excel. Kyiv: Morion, 408.
  14. Lip, G. Y. H., Collet, J.-P., Haude, M., Byrne, R., Chung, E. H. et. al. (2018). 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). EP Europace, 21 (2), 192–193. doi: http://doi.org/10.1093/europace/euy174
  15. Sambola, A., Mutuberría, M., García del Blanco, B., Alonso, A., Barrabés, J. A., Alfonso, F. et. al. (2016). Effects of Triple Therapy in Patients With Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Regarding Thromboembolic Risk Stratification. Circulation Journal, 80 (2), 354–362. doi: http://doi.org/10.1253/circj.cj-15-0923
  16. Calenda, B. W., Fuster, V., Halperin, J. L., Granger, C. B. (2016). Stroke risk assessment in atrial fibrillation: risk factors and markers of atrial myopathy. Nature Reviews Cardiology, 13 (9), 549–559. doi: http://doi.org/10.1038/nrcardio.2016.106

Downloads

Published

2019-06-25

How to Cite

Fedia, B. S. (2019). Treatment of patients with acute coronary syndrome and atrial fibrillation. ScienceRise: Medical Science, (3 (30), 28–36. https://doi.org/10.15587/2519-4798.2019.170467

Issue

No. 3 (30) (2019)

Section

Medical Science

License

Copyright (c) 2019 Ben Salem Fedia

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.